Recent advances in understanding, diagnosing and treating venous thrombosis [version 1; peer review: 2 approved]

by Noel C Chan, Jeffrey I Weitz
Published 2020-10-01

Anticoagulation for Patients with Venous Thromboembolism: When is Extended Treatment Required?

by Jeffrey I. Weitz, Paolo Prandoni, Peter Verhamme
Published 2020-10-01

Recent advances in the treatment of venous thromboembolism in the era of the direct oral anticoagulants [version 1; referees: 2 approved]

by Jeffrey I. Weitz, Iqbal H. Jaffer, James C. Fredenburgh
Published 2017-06-01

Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

by Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz
Published 2024-05-01

Trends in the proportion of women as reviewers, editors, and editorial board members of 15 North American and British medical journals from 2014 to 2019: A retrospective study

by Roxanna Wang, Robin Roberts, James C Fredenburgh, Mary Cushman, Jeffrey I Weitz
Published 2022-07-01

Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function.

by Calvin H Yeh, Alan R Stafford, Beverly A Leslie, James C Fredenburgh, Jeffrey I Weitz
Published 2016-01-01

Fibrous hydrogels under biaxial confinement

by Yang Li, Yunfeng Li, Elisabeth Prince, Jeffrey I. Weitz, Sergey Panyukov, Arun Ramachandran, Michael Rubinstein, Eugenia Kumacheva
Published 2022-06-01

Selection and characterization of a DNA aptamer inhibiting coagulation factor XIa

by David A. Donkor, Varsha Bhakta, Louise J. Eltringham-Smith, Alan R. Stafford, Jeffrey I. Weitz, William P. Sheffield
Published 2017-05-01

Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors

by Zoltan Szekanecz, Zhenyu Wang, Jeffrey I Weitz, Christina Charles-Schoeman, Ivana Vranic, David A Martin, Craig Hyde, Burak Sahin, Sara A Paciga
Published 2022-11-01

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

by Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz
Published 2018-04-01

Heavy menstrual bleeding in women on anticoagulant treatment for venous thromboembolism: Comparison of high‐ and low‐dose rivaroxaban with aspirin

by Kochawan Boonyawat, Anthonie W. A. Lensing, Martin H. Prins, Jan Beyer‐Westendorf, Paolo Prandoni, Ida Martinelli, Saskia Middeldorp, Akos F. Pap, Jeffrey I. Weitz, Mark Crowther
Published 2021-02-01

Extended anticoagulant therapy in venous thromboembolism: a balanced, fractional factorial, clinical vignette-based study

by Vincent ten Cate, Anthonie W.A. Lensing, Jeffrey I. Weitz, Jan Beyer-Westendorf, Philip S. Wells, Patrick Mismetti, Paolo Prandoni, Alexander T. Cohen, Bruce L. Davidson, Martin H. Prins
Published 2019-10-01

The contact activation system as a potential therapeutic target in patients with COVID‐19

by Joseph J. Shatzel, Emma P. DeLoughery, Christina U. Lorentz, Erik I. Tucker, Joseph E. Aslan, Monica T. Hinds, David Gailani, Jeffrey I. Weitz, Owen J. T. McCarty, Andras Gruber
Published 2020-05-01

Optimization of plasma-based BioID identifies plasminogen as a ligand of ADAMTS13

by Hasam Madarati, Veronica DeYoung, Kanwal Singh, Taylor Sparring, Andrew C. Kwong, James C. Fredenburgh, Cherie Teney, Marlys L. Koschinsky, Michael B. Boffa, Jeffrey I. Weitz, Colin A. Kretz
Published 2024-04-01

Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome

by Liping Zhang, Xiaoyu Yan, Partha Nandy, Stefan Willmann, Keith A. A. Fox, Scott D. Berkowitz, Amarnath Sharma, Anne Hermanowski-Vosatka, Stephan Schmidt, Jeffrey I. Weitz, Dirk Garmann, Gary Peters
Published 2019-07-01

Association Between Asymptomatic Proximal Deep Vein Thrombosis and Mortality in Acutely Ill Medical Patients

by Gary E. Raskob, Alex C. Spyropoulos, Alexander T. Cohen, Jeffrey I. Weitz, Walter Ageno, Yoriko De Sanctis, Wentao Lu, Jianfeng Xu, John Albanese, Chiara Sugarmann, Traci Weber, Concetta Lipardi, Theodore E. Spiro, Elliot S. Barnathan
Published 2021-03-01

Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD‐VTE

by Walter Ageno, Alfredo Farjat, Sylvia Haas, Jeffrey I. Weitz, Samuel Z. Goldhaber, Alexander G. G. Turpie, Shinya Goto, Pantep Angchaisuksiri, Joern Dalsgaard Nielsen, Gloria Kayani, Sebastian Schellong, Henri Bounameaux, Lorenzo G. Mantovani, Paolo Prandoni, Ajay K. Kakkar
Published 2021-02-01

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial

by Alex C. Spyropoulos, Mark Goldin, Walter Ageno, Gregory W. Albers, C. Gregory Elliott, William R. Hiatt, Jonathan L. Halperin, Gregory Maynard, P. Gabriel Steg, Jeffrey I. Weitz, Theodore E. Spiro, Wentao Lu, Jessica Marsigliano, Gary E. Raskob, Elliot S. Barnathan
Published 2022-07-01

Benefit–Risk Assessment of Rivaroxaban for Extended Thromboprophylaxis After Hospitalization for Medical Illness

by Gary E. Raskob, Walter Ageno, Gregory Albers, C. Gregory Elliott, Jonathan Halperin, Gregory Maynard, Philippe Gabriel Steg, Jeffrey I. Weitz, John Albanese, Zhong Yuan, Bennett Levitan, Wentao Lu, Eun Young Suh, Theodore Spiro, Concetta Lipardi, Elliot S. Barnathan, Alex C. Spyropoulos
Published 2022-10-01

Direct Oral Anticoagulants for Pulmonary Embolism: Importance of Anatomical Extent

by Marjolein P. A. Brekelmans, Harry R. Büller, Michele F. Mercuri, Walter Ageno, Cathy Z. Chen, Alexander T. Cohen, Nick van Es, Michael A. Grosso, Andria P. Medina, Gary Raskob, Annelise Segers, Thomas Vanassche, Peter Verhamme, Philip S. Wells, George Zhang, Jeffrey I. Weitz
Published 2018-01-01